Roberto Cairoli

ORCID: 0000-0001-6372-2623 · 4 papers in corpus
2024
Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management.
Antibiotics (Basel, Switzerland) ·doi:10.3390/antibiotics13050387

Central nervous system (CNS) lesions, especially invasive fungal diseases (IFDs), in immunocompromised patients pose a great challenge in diagnosis and treatment. We report the case of a 48-year-old man with acute myeloid leukaemia and prob…

article 2023
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an “Old-fashioned” Drug be Effective?
HemaSphere ·doi:10.1097/hs9.0000000000000867

Severe thrombocytopenia is a relatively uncommon event in myelodysplastic syndromes (MDS) and may occur in high-risk patients, advocating treatment with hypomethylating agents or with allogeneic bone marrow transplantation.1 In low-risk pat…

article 2022
Efficacy and Safety of Danazol in Patients with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms: A Multicenter Observational Study
·doi:10.1182/blood-2022-157430

Thrombocytopenia affects about two thirds of patients with myelodysplastic syndromes (MDS) and treatment is not standardized. Immunosuppressants, such as corticosteroids, cyclosporin or anti-thymocyte globulin show some efficacy, particular…

article 2018
Danazol Treatment for Thrombocytopenia in Lower-Risk Myelodysplastic Syndromes: A Pilot Real Life Experience
·doi:10.1182/blood-2018-99-115283

Abstract Background: Severe thrombocytopenia is an uncommon event in patients (pts) with lower-risk MDS, but it may significantly affect the prognosis. No specific pharmacological approaches other than hypometilating agents (not licensed in…